Linkedin Twitter
Project name:

A Ukrainian Research Institute offers the innovative technology of individual selection of antitumor drugs

Status: Idea
Creation date: 15-11-2021

Project objectives:


Scientists from the Ukrainian R&D Institute have developed a laboratory technique for the individual selection of antitumor drugs in the treatment of cancer patients with various types of solid malignant tumors. The technology allows increasing the clinical efficacy of the treatment of cancer patients into 2-4 times, as well as reducing the financial costs for the treatment by 3-5 times. The Ukrainian R&D institute is looking for partners to conclude license or technical cooperation agreements.


Due to the lack of effectiveness of modern standard drug treatment of malignant tumors, the relevance of individual treatment of a particular patient increases, taking into account the sensitivity of the tumor to anticancer drugs. Among antitumor drugs, cytostatics, targeted, immune drugs in standard dose regimes, activated small and ultra-small doses, as well as a polypharmacological immunocorrector (IC) can be used for anticancer therapy.
Ukrainian Research Institute proposes an individualized selection of the most effective anticancer drugs (chemo-, endocrine-, targeted, immunotherapy) is carried out using preliminary testing of the drug with the patient's blood in vitro and the evaluation of the predicted therapeutic effect. At the same time, the effect of the medicinal agent on the dynamics of the thiol-disulfide ratio (TDR) in the blood as an integral indicator of the redox balance is assessed. Considering that the TDR in the blood cells of an oncological patient has a direct correlation with the TDR in the tumor cells, the assessment of the effect of the pharmacological drug on the blood is a simultaneous indirect reflection of its antitumor effect. This technology makes it possible to predict the individual therapeutic effect of a wide range of pharmacological anticancer drugs since each of them ultimately leads to an individual dynamic effect on the TDR of the patient’s blood and tumor.
Before assigning of each course of drug treatment, the patient's blood is tested in vitro with competing drugs from various pharmacological groups (chemo-, endocrine-, targeted-, immunotherapy), among which the most effective in the optimal therapeutic dose is selected. Prediction of the individual therapeutic effect of pharmacotherapy is based on 24-72-hour monitoring of the dynamics of the thiol-disulfide ratio (TDR) in blood in vitro under the influence of the drug.
This technology can be used to form groups of patients (sensitive and insensitive to experimental pharmacotherapy) in clinical studies of new drugs.
This technology has been used in the treatment of cancer patients in Ukraine for the past 20 years.
The Research Institute is searching for medical laboratories, pharmacological companies, scientific organizations and medical institutions of oncological profile for signing the License or Technical cooperation agreement. The institution also offers access to rights for commercial use and allows the opportunity for further co-development of technology with companies from the pharmaceutical and medical sector or research institutions.

Advantages & innovations

The technology does not require expensive equipment, materials and reagents. Standard clinical or biochemical laboratory needed. The minimum amount of venous patient’s blood for analysis is to be used. The cost of the analysis is much less (in 5-10 times) than the existing alternative technologies for individual selecting of pharmacotherapy in oncology. The technology proposed by Ukrainian R&D Institute allows to increase the clinical efficacy of the treatment of cancer patients with metastatic forms of solid tumor disease into 2-4 times, as well as to reduce financial costs for treatment by 3-5 times compared with standard treatment protocols. Technology is applicable to the selection of a wide range of modern anticancer drugs.

Stage of development

Already on the market

Contact/ source: Enterprise Europe Network (


Quick contact Contact us for more informations